What is FoundationOne Liquid?
FoundationOne Liquid may help inform cancer care from a simple blood draw.
This laboratory developed liquid biopsy test provides targeted gene and microsatellite instability-high (MSI-H) results* that may help inform therapy selection and clinical trial options for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing expertly curated reports, FoundationOne Liquid empowers providers to make more informed clinical decisions.
70 genes and MSI-H*
Includes guideline-recommended genes and biomarkers to help guide therapy selection and identify clinical trial options for patients with solid tumors.
2 tubes of blood
Requires only two 8.5mL tubes of blood to identify targeted therapy, immunotherapy, and clinical trial options.
Learn more about the clinical utility of FoundationOne Liquid in a number of cancer types.
Non-small Cell Lung Cancer (NSCLC) EGFR Sample ReportDOWNLOAD SAMPLE REPORT
View a FoundationOne Liquid NSCLC sample report. This report shows results with an EGFR alteration detected.
Liquid Biopsy: From an Improbable Idea, New Potential EmergesREAD FULL BLOG POST
It’s always been an ambitious concept: By analyzing a patient’s blood, doctors might better understand their individual cancer, and thus better pinpoint what treatment options may be most effective. But yesterday’s ambition has become today’s reality—we’re living in an exciting time for this kind of test, known as liquid biopsy.
Uncovering Treatment Options for Patients with Non-Small Cell Lung Cancer (NSCLC)Download NSCLC Profiler
Our portfolio of tests analyzes all guideline-recommended genes and biomarkers for relevant alterations in patients with NSCLC including EGFR, ALK, ROS1, BRAF, NTRK,† METex14, PD-L1‡ and genomic signatures like TMB.
Prostate Cancer BRCA Sample ReportDOWNLOAD SAMPLE REPORT
View a FoundationOne Liquid Prostate Cancer sample report. This report shows results with an BRCA alteration detected.
Unlocking New Treatment Options for Patients with Metastatic Prostate CancerProstate Profiler
Our portfolio of tests analyzes all guideline-recommended genes and biomarkers for relevant alterations in patients with prostate cancer including: BRCA1, BRCA2, ATM, PALB2, FANCA†, RAD51D†, CHEK2, CDK12, and genomic signatures like MSI.*
FoundationOne Liquid Resources
Need More Details?
Our client services team is here to help, Monday through Friday 8AM – 8PM EST.
*FoundationOne Liquid only reports MSI when determined to be high
†Only currently tested on FoundationOne CDx
‡PD-L1 by Immunohistochemistry (IHC) can be ordered as a supplemental test and may inform eligibility for several immunotherapies across different cancer types
FoundationOne CDx is the only FDA-approved in vitro diagnostic test by Foundation Medicine. FoundationOne Liquid and FoundationOne Heme were developed and their performance characteristics determined by Foundation Medicine. They have not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed tests (LDTs) please see their respective Technical Specifications at www.foundationmedicine.com.